Rosen Law Firm Calls on Marinus Pharmaceuticals Investors to Seek Counsel Prior to Class Action Deadline

New York, June 19, 2024 -- Rosen Law Firm, a preeminent global investor rights firm, emphasizes the significance of investors in Marinus Pharmaceuticals, Inc. MRNS taking action to protect their rights. Shareholders who purchased securities in the company are urged to secure legal counsel before the impending deadline related to the securities class action lawsuit initially filed by the firm.

Investor Alert for Marinus Pharmaceuticals Shareholders

Investors who acquired Marinus Pharmaceuticals, Inc. MRNS stocks should be aware of their legal rights and may be eligible to recover losses. MRNS, a clinical-stage pharmaceutical firm based in Radnor, Pennsylvania, is dedicated to the creation and commercialization of novel therapies for rare seizure disorders. With its increasing focus on pharmaceutical innovation, the company has attracted a variety of investors seeking opportunities within the healthcare sector.

Class Action Deadline Approaching

Potential claimants should note that a deadline is fast approaching to join the class action suit that accuses Marinus Pharmaceuticals of possible securities violations. Rosen Law Firm is advocating for MRNS investors to promptly seek legal representation to participate in the class action case. This legal consideration is crucial for investors who want to recover any losses incurred from their investment in Marinus Pharmaceuticals.

About Rosen Law Firm

Rosen Law Firm operates internationally, representing investors worldwide and specializing in securities class actions and shareholder derivative litigation. Investors who choose Rosen Law Firm benefit from their extensive experience in providing legal guidance for those seeking to enforce their investment rights under complex securities laws.

investment, legal, deadline